Login
Bellicum Pharmaceuticals NASDAQ: BLCM
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders
| Name | Bellicum Pharmaceuticals |
| Ticker | BLCM |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 7.74 |
| 52W Low/High | 3.52 / 22.90 |
| Market cap | 39 M |
| 1Y Total Return |
-32.11%
Below Average |
| 1Y Volatility |
130.90%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders
Details
| Ticker | BLCM |
| Name | Bellicum Pharmaceuticals |
| ISIN | US0794811077 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 9/18/20
| Close Price | 7.74 |
| 52W Low/High | 3.52 / 22.90 |
| Market cap | 39 M |
| 1Y Total Return |
-32.11%
Below Average |
| 1Y Volatility |
130.90%
High Risk |
| Beta | 1.96 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -1,885.3% |
| Cash from Op. / Cur. Liabilities | -0.79 |
| Diluted Earnings / Share | -20.07 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 7.5 |
| Price / Book | -0.8 |
| Price / CF | -0.5 |
| Current Ratio | 0.9 |
| Cur.Liabilities / Tot.Liabilities | 0.8 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
5
|
3
|
1
|
0
|
0
|
-
|
|
| Gross Profit |
5
|
3
|
1
|
0
|
0
|
-
|
|
| R&D |
50
|
74
|
67
|
62
|
43
|
-
|
|
| EBITDA |
-78
|
-90
|
-83
|
-78
|
-59
|
-
|
|
| Operating Income |
-67
|
-100
|
-88
|
-82
|
-62
|
-
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
5
|
5
|
4
|
3
|
3
|
-
|
|
| EPS exc. Extra |
-20.07
|
-23.16
|
-26.40
|
-29.40
|
-23.10
|
-
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
72
|
90
|
162
|
168
|
150
|
180
|
|
| Cash, Eq & Invt ShortTerm |
66
|
61
|
135
|
135
|
106
|
119
|
|
| Total Current Assets |
68
|
59
|
132
|
133
|
108
|
122
|
|
| Total Non-Current Assets |
4
|
31
|
30
|
35
|
42
|
58
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
100
|
59
|
50
|
45
|
22
|
3
|
|
| Total Current Liabilities |
79
|
22
|
13
|
16
|
7
|
3
|
|
| Long Term Debt |
21
|
37
|
37
|
29
|
16
|
0
|
|
| Shareholder equity |
-49
|
30
|
113
|
123
|
127
|
177
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-62
|
-83
|
-68
|
-69
|
-44
|
-
|
|
| Depreciation |
5
|
8
|
5
|
3
|
2
|
-
|
|
| Cash from Investing |
28
|
41
|
-2
|
17
|
-24
|
-
|
|
| Capex |
15
|
1
|
6
|
10
|
7
|
-
|
|
| Cash from Financing |
55
|
9
|
70
|
82
|
16
|
-
|
|
| Stock Issued |
42
|
10
|
68
|
67
|
1
|
-
|
|
| Debt (LT) Issued |
-10
|
0
|
2
|
15
|
15
|
-
|
|
| Free Cash Flow |
-22
|
-41
|
-93
|
-78
|
-101
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
0.9
|
2.7
|
10.2
|
8.3
|
16.4
|
41.0
|
|
| Financial Leverage D/E |
-
|
1.44
|
0.32
|
0.25
|
0.12
|
0.00
|
|
| Return on Capital Avg |
-
|
-216.0%
|
-124.1%
|
-97.9%
|
-72.3%
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available